Kim Hyeyoon, Hall David Ross, Nierves Lorenz, Lin Tai-Tu, Kitata Reta Birhanu, Shi Tujin, Liu Tao
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA.
Expert Rev Proteomics. 2025 Jul;22(7):255-272. doi: 10.1080/14789450.2025.2529185. Epub 2025 Jul 10.
The landscape of biomarker development has evolved with advanced analytical technologies, particularly affinity- and mass spectrometry-based techniques. These advancements have deepened our understanding of disease mechanisms, enabling the development of precise diagnostic tools and personalized medicine. Protein biomarkers, which play pivotal roles in biological processes, have become invaluable in diagnosing and monitoring diseases, aided by their presence in various biological samples and the availability of established detection methods.
This review covers the role of protein biomarkers in clinical practice, the development and dimensionality of protein biomarkers, advancements in detection technologies, a comparison of these technologies, and future directions in biomarker discovery and disease mechanism elucidation.
Advances in biomarker technologies have the potential to transform diagnostics and personalized treatment but face challenges such as high costs and technical complexity. Enhancing reproducibility and integrating multi-omics approaches may offer better insights. The field should evolve toward high-throughput, automated methods, continuously adapting research, and clinical practices.
随着先进分析技术的发展,尤其是基于亲和力和质谱的技术,生物标志物的开发格局已经发生了演变。这些进展加深了我们对疾病机制的理解,推动了精确诊断工具和个性化医疗的发展。蛋白质生物标志物在生物过程中起着关键作用,由于它们存在于各种生物样本中且有成熟的检测方法,在疾病诊断和监测中变得至关重要。
本综述涵盖了蛋白质生物标志物在临床实践中的作用、蛋白质生物标志物的开发和维度、检测技术的进展、这些技术的比较,以及生物标志物发现和疾病机制阐明的未来方向。
生物标志物技术的进步有可能改变诊断和个性化治疗,但面临着高成本和技术复杂性等挑战。提高可重复性和整合多组学方法可能会提供更好的见解。该领域应朝着高通量、自动化方法发展,不断调整研究和临床实践。